

Effect of delayed cell infusion in patients with large B-cell lymphoma treated with chimeric antigen receptor T-cell therapy

Andrew P. Jallouk,^{1,2} Naishu Kui,³ Ryan Sun,³ Jason R. Westin,¹ Raphael E. Steiner,¹ Ranjit Nair,¹ Loretta J. Nastoupil,¹ Luis E. Fayad,¹ Ajlan Al Zaki,¹ Misha Hawkins,¹ Sherry Adkins,¹ Mansoor Noorani,¹ Kaberi Das,⁴ Jared Henderson,¹ Elizabeth J. Shpall,⁵ Partow Kebriaei,⁵ Jeremy Ramdial,⁵ Christopher R. Flowers,¹ Sattva S. Neelapu,¹ Sairah Ahmed^{1,5#} and Paolo Strati^{1#}

¹Department of Lymphoma and Myeloma, the University of Texas MD Anderson Cancer Center, Houston, TX; ²Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN; ³Department of Biostatistics, the University of Texas MD Anderson Cancer Center, Houston, TX; ⁴Department of Leukemia, the University of Texas MD Anderson Cancer Center, Houston, TX and ⁵Department of Stem Cell Transplantation and Cellular Therapy, the University of Texas MD Anderson Cancer Center, Houston, TX, USA

#SA and PS contributed equally as senior authors.

Correspondence: S. Ahmed
SAhmed3@mdanderson.org

P. Strati
pstrati@mdanderson.org

Received: October 12, 2023.
Accepted: November 23, 2023.
Early view: November 30, 2023.

<https://doi.org/10.3324/haematol.2023.284453>

©2024 Ferrata Storti Foundation

Published under a CC BY-NC license



Cause of death	On-time Cell Infusion (N=89)	Delayed Cell infusion (N=24)
	Number (%)	
Disease recurrence/progression	68 (76)	14 (59)
Infection	9 (10)	1 (4)
Secondary malignancy	4 (4)	2 (8)
ICANS	4 (4)	0 (0)
Intracranial hemorrhage	0 (0)	1 (4)
Cardiac arrest	1 (1)	0 (0)
Interstitial pneumonia	1(1)	0 (0)
Unknown	2 (2)	5 (21)

Supp. Table 1. Cause of death in deceased patients

ICANS, immune effector cell-associated neurotoxicity syndrome

Total (N=22)	1 Day Delay (N=18)	2-5 Day Delay (N=11)	>5 Day Delay (N=11)	P Value
	Number (%), median [range]			
Age (years)	57 [24-69]	61 [24-85]	66 [39-73]	0.350
Male	14 (77.8)	5 (45.5)	7 (63.6)	0.255
ECOG 2-4	5 (27.8)	2 (18.2)	1 (9.1)	0.543
IPI score 3-5	12 (66.7)	8 (72.7)	7 (63.6)	0.999
LDH (U/L) > UNL	14 (77.8)	10 (90.9)	7 (63.6)	0.399
ANC < 1200/ μ L*	2 (11.1)	3 (27.3)	7 (63.6)	0.010
Plts < 75K / μ L*	8 (44.4)	3 (27.3)	6 (54.5)	0.431
Hgb < 9.0 g/dL*	9 (50)	4 (36.4)	8 (72.7)	0.246
CRP > 3.0 mg/dL*	12 (66.7)	6 (54.5)	8 (72.7)	0.764
Ferritin > 2,000 ng/mL*	5 (27.8)	2 (18.2)	3 (27.3)	0.902
CrCl (mL/min)	68 [25-141]	92 [78-132]	92 [36-135]	0.207
LDC dose reduced	4 (22.2)	2 (18.2)	1 (9.1)	0.868
Total Flu dose (mg/m ²)	90 [45-90]	90 [60-90]	90 [60-90]	0.696
Total Cy dose (mg/m ²)	1500 [1000-1500]	1500 [1000-1500]	1500 [1000-1500]	0.917
Prior therapies \geq 3	16 (88.9)	9 (81.8)	11 (100)	0.559
Bridging therapy use	9 (50)	7 (63.6)	5 (45.5)	0.779
Refractory disease	13 (72.2)	8 (72.7)	9 (81.8)	0.902
Previous autologous SCT	8 (44.4)	0 (0)	3 (27.3)	0.027
Previous allogeneic SCT	0 (0)	1 (9.1)	1 (9.1)	0.492

Supp. Table 2. Baseline characteristics of patients with 1 day delay, 2-5 day delay and >5 day delay

ECOG, European Cooperative Oncology Group; IPI, International Prognostic Index; LDH,

lactate dehydrogenase; UNL, upper limit of normal; ANC, absolute neutrophil count; Plts, platelets; Hgb, hemoglobin; CRP, C-reactive protein; CrCl, creatinine clearance; LDC, lymphodepleting chemotherapy; Flu, fludarabine; Cy, cyclophosphamide; SCT, stem cell transplant

* Cutoff values derived from CAR-HEMATOTOX score²²

Cause of delay	1 Day Delay (N=18)	2-5 Day Delay (N=11)	>5 Day Delay (N=11)
	Number (%)		
Concern for infection	14 (77.7)	9 (81.8)	11 (100)
Need for disease-related procedures	1 (5.6)	2 (18.2)	0 (0)
Logistical delays	3 (16.7)	0 (0)	0 (0)

Supp. Table 3. Cause of infusion delay in patients with 1 day delay, 2-5 day delay and >5 day delay